price
OV
NASDAQ · OVID
Ovid Therapeutics Inc.
Healthcare · Biotechnology
$2.54
Down-$0.02 (-0.78%)
Updated Nov 2, 2026, 12:58 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 117.35M
- P/E ratio
- -0.06
- Dividend yield
- 0.00%
- 52-week range
- $1.18 – $3.11
- Volume
- 3.15M
- Avg. volume
- 2.89M
Price performance · OVID
OVID price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
OVID closed at $2.54 after 20 trading sessions, up 8.55% for the selected period.
- Last close
- $2.54
- Period change
- +8.55%
- Period low
- $2.15
- Period high
- $2.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $2.51 | $2.70 | $2.44 | $2.54 | 3.15M |
| Oct 29, 2026 | $2.45 | $2.58 | $2.405 | $2.56 | 2.04M |
| Oct 28, 2026 | $2.26 | $2.495 | $2.205 | $2.45 | 2.06M |
| Oct 27, 2026 | $2.18 | $2.28 | $2.10 | $2.26 | 1.69M |
| Oct 26, 2026 | $2.19 | $2.22 | $2.1213 | $2.155 | 844.07K |
| Oct 23, 2026 | $2.31 | $2.32 | $2.12 | $2.16 | 2.02M |
| Oct 22, 2026 | $2.45 | $2.50 | $2.34 | $2.37 | 1.18M |
| Oct 21, 2026 | $2.37 | $2.65 | $2.345 | $2.47 | 5.01M |
| Oct 20, 2026 | $2.19 | $2.46 | $2.175 | $2.36 | 3.67M |
| Oct 19, 2026 | $2.18 | $2.225 | $2.14 | $2.17 | 1.64M |
| Oct 16, 2026 | $2.26 | $2.30 | $2.11 | $2.15 | 1.33M |
| Oct 15, 2026 | $2.21 | $2.31 | $2.19 | $2.26 | 1.33M |
| Oct 14, 2026 | $2.18 | $2.255 | $2.09 | $2.19 | 1.64M |
| Oct 13, 2026 | $2.41 | $2.415 | $2.18 | $2.19 | 1.64M |
| Oct 12, 2026 | $2.45 | $2.4933 | $2.394 | $2.41 | 876.04K |
| Oct 9, 2026 | $2.37 | $2.475 | $2.33 | $2.46 | 1.41M |
| Oct 8, 2026 | $2.32 | $2.36 | $2.29 | $2.34 | 1.65M |
| Oct 7, 2026 | $2.36 | $2.46 | $2.34 | $2.36 | 1M |
| Oct 6, 2026 | $2.42 | $2.44 | $2.27 | $2.37 | 1.74M |
| Oct 5, 2026 | $2.38 | $2.47 | $2.29 | $2.34 | 1.2M |
Latest OVID news
The latest Smart Investors Daily articles mentioning OVID.
Stock researchCompany · Financials
Company
Market Activity
Research & News
Loading stock research…

